Three days on and $3.9bn down: Pfizer's offer sinks in quicksand
This article was originally published in Scrip
Executive Summary
Pfizer's recently revised offer for AstraZeneca was built on the quicksand of market valuation. Subsequently, the perils of basing merger bids largely on stock rather than on cash have become clear.